Science News & Science Current Events
 
Email a Friend Send to a friend
Printer Friendly Print Experts urge industry and international donors to prepare pneumococcal vaccines

Experts urge industry and international donors to prepare pneumococcal vaccines

May 19, 2006

Millions of deaths could be prevented by routine immunisation against a major cause of pneumonia and meningitis in the developing world

London, UK- In today's online edition of The Lancet, a group of leading global health experts have come together to call for vaccine manufacturers and international donors to negotiate affordable pricing of pneumococcal conjugate vaccines and for governments of developing world countries and their partners to establish disease surveillance networks and begin preparations for pneumococcal vaccine introduction.




The experts believe that urgent action to introduce routine childhood pneumococcal vaccination is needed because of the enormous burden of the disease - the World Health Organization (WHO) estimates that about 1.6 million people, including up to one million children under five years old, die every year of pneumococcal pneumonia, meningitis, and sepsis.1 In populations with high child mortality rates, pneumonia is the leading infectious cause of mortality and accounts for about 20-25% of all child deaths.2

This call to action comes on the eve of a meeting of G8 ministers to discuss funding vaccines. This seems to be the latest step in major changes over the last five years in financing of immunization, including the creation of the GAVI Alliance (Global Alliance for Vaccines and Immunization) Fund. Dr Orin Levine, the lead author of the article and Executive Director of PneumoADIP - a non-governmental organization that aims to shorten the time between use of a vaccine in industrialized nations and their introduction in the developing world - commented: "We hope that with such mechanisms in place, all developing countries will begin to consider that millions of children can now be saved by the simple addition of this vaccine to existing immunization programs."

Dr Thomas Cherian, Co-ordinator, Ad Interim, EPI, WHO, and co-author of the article added: "Pneumococcal disease is a major global health issue; what is promising is that a seven-valent vaccine that is effective against seven common strains of the disease is already licensed and in use in over 60 countries and that formulations containing additional serotypes of the organism that are also relevant for developing countries are under development. The WHO considers pneumococcal vaccines to be a priority and recognizes the urgency to make these vaccines available for children in developing countries."

There are other pneumococcal vaccines in development, which contain additional serotypes targeting strains of the disease that commonly cause death and disability in the developing world; however, these will not be available for several years. Introducing the seven-valent vaccine now means that lives can start to be saved immediately. This vaccine, manufactured by Wyeth, is effective, well-tolerated and can be delivered through existing immunization systems. Surveillance data from the U.S.indicate that the herd immunity* effect from routine childhood pneumococcal vaccination prevents twice as many cases as the direct effects of vaccination alone - protecting vulnerable adults as well as children.

Responding to The Lancet paper, Julian Lob-Levyt, Executive Secretary, GAVI Alliance, said, "There is convincing evidence of the benefits of vaccines for major child killers, especially when such a simple health intervention could help in meeting UN Millennium Development Goal no. 4: to reduce child mortality by two thirds by 2015. GAVI will be looking closely at how best to assist countries where pneumococcal disease represents a significant burden on public health."

Jean Stéphenne, President of GlaxoSmithKline Biologicals, the vaccines division of GlaxoSmithKline PLC, also welcomed the call to action in The Lancet and said, "GSK Bio has invested many years in the development of a vaccine that protects against the 10 most important strains of pneumococcus serotypes worldwide, and our candidate is now being studied in a global clinical program. We have a long history of supplying vaccines in developing countries and are committed to working to make our pneumococcal vaccine available worldwide at sustainable prices. We hope that our partners in governments, donor agencies, charities, and international organizations will step up with a firm purchase commitment that will allow us to save as many lives as possible."

James Connolly, Executive Vice President and General Manager of Wyeth Pharmaceuticals vaccine's business unit, concurred with the call to action and stated, "Prevnar has been launched in 60 countries, and has had a significant impact on the health of children where it is in use. In the U.S., three years after the routine use of Prevnar, there has been a 94 percent reduction in invasive pneumococcal disease caused by the disease serotypes included in the vaccine. We are actively working with international agencies to help provide access to Prevnar for children in the developing world.

Meanwhile, Wyeth researchers are continuing to work on new versions of Prevnar, including a version that will address 13 of the most prevalent serotypes of invasive pneumococcal disease, which will expand its usefulness globally for both children and adults."

Strategic Communications



Related Pneumococcal Disease Current Events and Pneumococcal Disease News Articles Pneumococcal Disease Current Events and Pneumococcal Disease News RSS Pneumococcal Disease Current Events and Pneumococcal Disease News RSS
Despite vaccine, public should not get complacent about pneumococcal disease
Although the childhood pneumococcal conjugate vaccine has been a boon in reducing the incidence invasive pneumococcal disease (IPD), the public and the medical community must not get complacent, as non-vaccine strains, some resistant to antibiotics, are on the rise, say scientists at a meeting today in Boston.

Pneumococcal conjugate vaccines can improve the lives of HIV-infected children
An international team of experts has published the first comprehensive review of evidence on pneumococcal conjugate vaccination (PCV) for children with HIV infection.

Number of cases of most vaccine-preventable diseases in US at all-time low
A comparison of illness and death rates for 13 vaccine-preventable diseases in the U.S., before and after use of the vaccine, indicates there have been significant decreases in the number of cases, hospitalizations and deaths for each of the diseases examined.

Patients with pneumonia who received pneumococcal vaccine have lower rate of death, ICU admission
Among patients hospitalized with community-acquired pneumonia, those who had previously received the pneumococcal vaccine had a lower risk of death and admission to the intensive care unit than patients who were not vaccinated.

Serious illness among children with sickle cell disease reduced with vaccine
A vaccine introduced in 2000 has reduced by more than 90 percent the rate of a serious bacterial illness among young children with sickle cell disease (SCD), who are particularly susceptible to it.

Increase seen in pneumococcal infections not covered by childhood vaccine
Alaska Native children are experiencing increased rates of serious infections caused by strains of pneumococcal bacteria that are not covered by the current childhood pneumococcal vaccine, indicating the importance of ongoing surveillance of vaccine effectiveness.

Preventing pneumonia in children helps prevent pneumonia in older adults
The incidence of pneumonia among older adults has decreased substantially, linked to the introduction of a pneumonia vaccine for children in 2000.

World Experts Unite in Urgent Effort to Fight Deadly Disease
* Up to One Million Child Deaths are Preventable * * New Evidence Shows HIV-Infected Children & Infants are Particularly Vulnerable * Leaders in the fight against disease today emphasized the importance of preventing unnecessary child deaths from Streptococcus pneumoniae - a disease currently responsible for killing between 800,000 and one million children every year, mostly in developing countries. The reaffirmed consensus on the need for new interventions to fight the disease came on the eve of the fourth International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-4) in Helsinki. The 2004 symposium is being organized by the National Public Health Institute of Finland and atten
More Pneumococcal Disease Current Events and Pneumococcal Disease News Articles
The Clinical Impact of Pneumococcal Disease And Strategies for Its Prevention (International Congress & Symposium)
by Richard T. Mayon-White

Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United ... from: Morbidity and Mortality Weekly Report
by A. Reingold, J. Hadler, M.M. Farley, L. Harrison, R. Lynfield, J. Besser, N. Bennett, A. Thomas, W. Schaffner, B. Beall, T. Pilishvili, C.G. Whitney, M. Moore, D.C. Burton

This digital document is an article from Morbidity and Mortality Weekly Report, published by Thomson Gale on September 16, 2005. The length of the article is 2625 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Prevnar 'herd immunity' tied to drop in pneumococcal disease: results from large California study.(News): An article from: Pediatric News
by Doug Brunk

This digital document is an article from Pediatric News, published by International Medical News Group on December 1, 2003. The length of the article is 894 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Invasive pneumococcal disease cases drop. (Vaccine's Impact).: An article from: Family Practice News
by Miriam E. Tucker

This digital document is an article from Family Practice News, published by International Medical News Group on November 1, 2002. The length of the article is 4225 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

New Conjugate Pneumococcal Vaccine Cuts Suppurative Disease.(Brief Article): An article from: Family Practice News
by Carl Sherman

This digital document is an article from Family Practice News, published by International Medical News Group on April 15, 2001. The length of the article is 507 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Outbreak of invasive pneumococcal disease in a jail - Texas, 1989.: An article from: Morbidity and Mortality Weekly Report

This digital document is an article from Morbidity and Mortality Weekly Report, published by U.S. Government Printing Office on November 3, 1989. The length of the article is 695 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Complicated pneumococcal disease. (ID Consult).(infectious diseases)(Brief Article): An article from: Pediatric News
by Christopher J. Harrison

This digital document is an article from Pediatric News, published by International Medical News Group on September 1, 2002. The length of the article is 814 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005.(RESEARCH): An article from: Emerging Infectious Diseases
by Michael G. Bruce, Shelley L. Deeks, Tammy Zulz, Dana Bruden, Christine Navarro, Marguerite Lovgren, Louise Jette, Karl Kristinsson, Gudrun Sigmundsdottir, Knud Brinklov Jensen, Oistein Lovoll, J. Pekka Nuorti, Elja Herva, Anders Nystedt, Anders Sjostedt

This digital document is an article from Emerging Infectious Diseases, published by Thomson Gale on January 1, 2008. The length of the article is 7946 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Outbreak of invasive pneumococcal disease--Alaska, 2003-2004.: An article from: Morbidity and Mortality Weekly Report
by G. Jorgenson, R. Singleton, J. Butler, T. Cottle, T. Hennessy, D. Hurlburt, K. Rudolph, D. Parks, L. Hammitt

This digital document is an article from Morbidity and Mortality Weekly Report, published by U.S. Government Printing Office on January 28, 2005. The length of the article is 1872 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Two- and three-dose PCV7 schedules aren't equivalent.(Infectious Diseases)(pneumococcal conjugate vaccine): An article from: Family Practice News
by Bruce K. Dixon

This digital document is an article from Family Practice News, published by Thomson Gale on December 1, 2007. The length of the article is 843 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Two-...

© 2008 BrightSurf.com